Fig. 3From: Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort studyFrequency of symptoms during a median follow-up of 7.9 months based on 101,233 weekly diaries from participants with (n = 144) and without (n = 4668) specific SARS-CoV-2 antibodies at baseline. Symptoms are sorted by increasing risk ratio. Error bars show 95% Wilson confidence intervals. P values calculated by two-sample proportion testBack to article page